Kaposi's sarcoma (Therapy)

European Marketing Authorization Received for Doxil To Treat AIDS-Related KS

Published in Cancer Weekly, July 15th, 1996

Sequus Pharmaceuticals, Inc., Menlo Park, California, announced that the European Commission has granted a marketing authorization, in the 15 countries of the European Union (EU), for its proprietary anti-cancer drug, Doxil, which have been scheduled for marketing in Europe under the trade name Caelyx [doxorubicin HCl (pegylated liposomal)].

This authorization followed the positive opinion in February 1996 by the Committee of Proprietary and Medicinal Products (CPMP). Caelyx is a long-circulating Stealth liposome formulation of doxorubicin, an anticancer drug. This drug is marketed in the United States under the tradename Doxil.

The approval was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry